Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tubulin alpha-1A (TUBA1A) is a major structural component of microtubules, which are essential cytoskeletal filaments formed by the polymerization of alpha- and beta-tubulin heterodimers [1, 11]. It is highly expressed in the developing brain and plays a critical role in neuronal migration, axon guidance, and intracellular transport [2, 5, 14]. Mutations in the TUBA1A gene are associated with a spectrum of brain malformations known as tubulinopathies, including lissencephaly and pachygyria, which lead to severe neurological deficits and epilepsy [4, 14, 15]. In clinical practice, tubulin is a primary target for various anti-cancer drugs, such as taxanes and vinca alkaloids, which disrupt microtubule dynamics to induce mitotic arrest and apoptosis [6, 11, 12]. These drugs are generally divided into stabilizing agents, which enhance polymerization, and destabilizing agents, which inhibit it [12]. While most existing drugs target the beta-subunit or the heterodimer interface, TUBA1A remains a key structural element whose regulation and interaction with microtubule-associated proteins are vital for cellular integrity and development [10, 11]. The precise regulation of TUBA1A is essential for the dynamic instability of microtubules, a process required for proper spindle formation during mitosis [11, 12].
Microtubule-targeting agents (MTAs) bind to tubulin to either stabilize (e.g., taxanes) or destabilize (e.g., vinca alkaloids) microtubules, leading to mitotic arrest and apoptosis.
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tubulin alpha-1A chain (TUBA1A) (TUBA1A).